ID   CLBL-1
AC   CVCL_L322
SY   CLBL1
DR   ChEMBL-Cells; CHEMBL4295489
DR   ChEMBL-Targets; CHEMBL4296408
DR   GEO; GSM1974779
DR   GEO; GSM2143059
DR   GEO; GSM2282267
DR   PubChem_Cell_line; CVCL_L322
DR   Wikidata; Q54813573
RX   PubMed=20153049;
RX   PubMed=22761949;
RX   PubMed=23365669;
RX   PubMed=27197945;
RX   PubMed=27257868;
RX   PubMed=27639374;
RX   PubMed=29674676;
RX   PubMed=31175136;
RX   PubMed=32651429;
CC   Part of: FACC canine tumor cell line panel.
CC   Doubling time: 19 hours (PubMed=27257868).
CC   Sequence variation: Mutation; VGNC; 54284; CCND3; Simple; p.Arg358fs (c.1071_1075delCAGAG); Zygosity=Heterozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Ala127Val (c.380C>T); Zygosity=Heterozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Arg257His (c.770G>A); Zygosity=Heterozygous (PubMed=31175136).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Caution: This cell line is owned by the University of Veterinary Medicine, Vienna who is the sole authorized distributor for both commercial and non-commercial research use.
CC   Derived from site: In situ; Lymph node; UBERON=UBERON_0000027.
CC   Cell type: B-cell; CL=CL_0000236.
CC   Breed/subspecies: Bernese mountain dog.
ST   Source(s): PubMed=27197945; PubMed=31175136
ST   Dog FHC2010: 231
ST   Dog FHC2054: 156,164
ST   Dog FHC2079: 271
ST   Dog PEZ1: 119
ST   Dog PEZ3: 119,124
ST   Dog PEZ5: 115
ST   Dog PEZ6: 183,187
ST   Dog PEZ8: 236,240
ST   Dog PEZ12: 274,277
ST   Dog PEZ20: 176
DI   NCIt; C128121; Canine lymphoma
OX   NCBI_TaxID=9615; ! Canis lupus familiaris (Dog)
SX   Male
AG   8Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 29-06-23; Version: 21
//
RX   PubMed=20153049; DOI=10.1016/j.leukres.2010.01.021;
RA   Rutgen B.C., Hammer S.E., Gerner W., Christian M.,
RA   de Arespacochaga A.G., Willmann M., Kleiter M., Schwendenwein I.,
RA   Saalmuller A.;
RT   "Establishment and characterization of a novel canine B-cell line
RT   derived from a spontaneously occurring diffuse large cell lymphoma.";
RL   Leuk. Res. 34:932-938(2010).
//
RX   PubMed=22761949; DOI=10.1371/journal.pone.0040078;
RA   Rutgen B.C., Willenbrock S., Reimann-Berg N., Walter I.,
RA   Fuchs-Baumgartinger A., Wagner S., Kovacic B., Essler S.E.,
RA   Schwendenwein I., Nolte I., Saalmuller A., Murua Escobar H.;
RT   "Authentication of primordial characteristics of the CLBL-1 cell line
RT   prove the integrity of a canine B-cell lymphoma in a murine in vivo
RT   model.";
RL   PLoS ONE 7:E40078-E40078(2012).
//
RX   PubMed=23365669; DOI=10.1371/journal.pone.0054464;
RA   Wells J.W., Evans C.H., Scott M.C., Rutgen B.C., O'Brien T.D.,
RA   Modiano J.F., Cvetkovic G., Tepic S.;
RT   "Arginase treatment prevents the recovery of canine lymphoma and
RT   osteosarcoma cells resistant to the toxic effects of prolonged
RT   arginine deprivation.";
RL   PLoS ONE 8:E54464-E54464(2013).
//
RX   PubMed=27197945; DOI=10.1111/vco.12192;
RA   Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.;
RT   "The Flint Animal Cancer Center (FACC) canine tumour cell line panel:
RT   a resource for veterinary drug discovery, comparative oncology and
RT   translational medicine.";
RL   Vet. Comp. Oncol. 15:481-492(2017).
//
RX   PubMed=27257868; DOI=10.1371/journal.pone.0156689;
RA   Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.;
RT   "Intrinsic radiosensitivity and cellular characterization of 27 canine
RT   cancer cell lines.";
RL   PLoS ONE 11:E0156689-E0156689(2016).
//
RX   PubMed=27639374; DOI=10.1186/s12917-016-0836-z;
RA   Roode S.C., Rotroff D.M., Richards K.L., Moore P.F., Motsinger-Reif A.A.,
RA   Okamura Y., Mizuno T., Tsujimoto H., Suter S.E., Breen M.;
RT   "Comprehensive genomic characterization of five canine lymphoid tumor
RT   cell lines.";
RL   BMC Vet. Res. 12:207.1-207.16(2016).
//
RX   PubMed=29674676; DOI=10.1038/s41598-018-23207-7;
RA   Taher L., Beck J., Liu W., Roolf C., Soller J.T., Rutgen B.C.,
RA   Hammer S.E., Chodisetti M., Sender S., Sterenczak K.A., Fuellen G.,
RA   Junghanss C., Brenig B., Nolte I., Schutz E., Murua Escobar H.;
RT   "Comparative high-resolution transcriptome sequencing of lymphoma cell
RT   lines and de novo lymphomas reveals cell-line-specific pathway
RT   dysregulation.";
RL   Sci. Rep. 8:6279-6279(2018).
//
RX   PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346;
RA   Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.;
RT   "Identifying candidate druggable targets in canine cancer cell lines
RT   using whole exome sequencing.";
RL   Mol. Cancer Ther. 18:1460-1471(2019).
//
RX   PubMed=32651429; DOI=10.1038/s41598-020-68470-9;
RA   Mizuno T., Kato Y., Kaneko M.K., Sakai Y., Shiga T., Kato M.,
RA   Tsukui T., Takemoto H., Tokimasa A., Baba K., Nemoto Y., Sakai O.,
RA   Igase M.;
RT   "Generation of a canine anti-canine CD20 antibody for canine lymphoma
RT   treatment.";
RL   Sci. Rep. 10:11476-11476(2020).
//